What does the growing prominence of Asia mean for pharmaceutical safety management?

Future Medicinal Chemistry

Volumn 2, Issue 10, 2010, Pages 1503-1506

  Geary, Stewart ^a  

^a EISAI CO LTD   (Japan)

Author keywords

chinese traditional medicines; counterfeit; fixed combination; HLA B 1502; pharmacovigilance

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN;

ASIA; CAMBODIA; CHINA; CHINESE MEDICINE; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; INDIA; JAPAN; KOREA; PHARMACEUTICAL CARE; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TAIWAN; TOXIC EPIDERMAL NECROLYSIS; UNITED STATES; VIET NAM;

ASIA; CLINICAL TRIALS AS TOPIC; COUNTERFEIT DRUGS; DRUG AND NARCOTIC CONTROL; DRUG COMBINATIONS; DRUGS, CHINESE HERBAL; FRAUD; HLA-B ANTIGENS; HUMANS; STEVENS-JOHNSON SYNDROME;

EID: 77958023456     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.238     Document Type: Editorial

References (18)

1. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nature Rev. Drug Disc. 7, 13-14 (2008
2. Saint-Raymond A, Sweeney F. Clinical trials in developing countries: risk or opportunity? Future Med. Chem. 1(7), 1193-1195 (2009
3. Chung W-H, Hung S-I, Hong H-S et al. A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004
4. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome. . .ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006
5. Kaniwa N, Saito Y, Aihara M et al. HLA-B locus in Japanese patients with antiepileptics and allopurinaol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11), 1617-1622 (2008
6. Hata Y, Uehara H. A case where herbal medicine sho-seiryu-to induced interstitial pneumonitis. Nihon Kokyuki Gakkai Zasshi. 43(1), 23-31 (2005
7. Katayama H, Hamada H, Yokoyama A et al. A case of interstitial pneumonia caused by gosha-jinki-gan. Nippon Ronen Igakkai Zasshi. 41(6), 675-678 (2004
8. Yang CS, Lin C-H, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am. J. Kidney Dis. 35(2), 313-318 (2000
9. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J. Natl Cancer Inst. 102, 179-189 (2010
10. Gautam CS, Aditya S. Irrational drug combinations: need to sensitize undergraduates. Indian J. Pharmacol. 38, 169-170 (2006
11. Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br. J. Clin. Pharmacol. 65(5), 795-796 (2007
12. Newton PN, Green MD, Fernandez FM. Impact of poor-quality medicines in the 'developing' world. Trends Pharmacol. Sci. 31, 99-101 (2010
13. Report of the Food and Drug Administration. Combating Counterfeit Drugs. February 18, 2004.
14. US Food and Drug Administration www.fda.gov/Drugs/DrugSafety/ dugSafetyInformationforPatientsandProviders/ ucm124718.htm (Accessed 12 July 2010
15. Varawalla N. Conducting clinical trials in Asia. Applied Clinical Trials website. http://appliedclinicaltrialsonline.findpharma. com/ appliedclinicaltrials/CRO%2fSponsor/ Conducting-Clinical-Trials-in-Asia/ ArticleStandard/Article/detail/334577 (Accessed 23 July, 2010
16. ICH website www.ich.org/cache/compo/276-254-251. html (Accessed July 13, 2010
17. The WHO www.who.int/medicines/services/counterfeit/ impact/ TheNewEstimatesCounterfeit.pdf (Accessed 13 July 2010
18. PSI www.psi-inc.org/geographicDistributions.cfm (Accessed 13 July 2010